[1]贾 方,王秋月,崔文静,等.金复康口服液对Lewis肺癌荷瘤小鼠PD-1、PD-L1表达及相关免疫因子的影响*[J].陕西中医,2020,(10):1347-1350,1417.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.001]
　JIA Fang,WANG Qiuyue,CUI Wenjing,et al.Effect of Jinfukang oral liquid on the expression of PD-1,PD-L1 and related immune factors in tumor microenvironment of mice bearing Lewis lung carcinoma[J].,2020,(10):1347-1350,1417.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.001]
点击复制

金复康口服液对Lewis肺癌荷瘤小鼠PD-1、PD-L1表达及相关免疫因子的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年10期
页码:
1347-1350,1417
栏目:
基础研究
出版日期:
2020-10-05

文章信息/Info

Title:
Effect of Jinfukang oral liquid on the expression of PD-1,PD-L1 and related immune factors in tumor microenvironment of mice bearing Lewis lung carcinoma
作者:
贾 方; 王秋月; 崔文静; 张 轶; 王菊勇△
上海中医药大学附属龙华医院(上海 200032)
Author(s):
JIA Fang; WANG Qiuyue; CUI Wenjing; et al.
Longhua Hospital,Shanghai University of Traditional Chinese Medicine(Shanghai 200032)
关键词:
金复康口服液;  非小细胞肺癌;  程序性死亡因子1;  程序性死亡因子配体1;  肿瘤微环境;  免疫调节
Keywords:
Jinfukang oral liquid;  Non-small cell lung cancer;  Programmed death receptor 1;  Programmed death ligand 1;  Tumor microenvironment;  Immune regulation
分类号:
R734.2
DOI:
DOI:10.3969/j.issn.1000-7369.2020.10.001
文献标志码:
A
摘要:
目的:观察金复康口服液对Lewis肺癌小鼠肿瘤微环境中程序性死亡受体1(PD-1)、配体(PD-L1)表达及相关免疫因子的影响。方法:采用Lewis肺癌细胞株培养移植法建立肺癌荷瘤小鼠模型,而后随机分为模型组、中药低、中、高剂量组每组8只; 实验第1天开始中药低、中、高剂量组小鼠分别按15、30、60 g/(kg·d)灌胃给药,模型组按照等量生理盐水给药,1次/d,连续给药14 d; 称取各组小鼠的瘤质量,计算抑瘤率; 荧光定量PCR检测荷瘤小鼠肿瘤组织中PD-1和PD-L1的mRNA,Western blot法检测肿瘤组织PD-1、PD-L1的蛋白表达水平,HE染色观察肺组织,同时ELISA法检测血清中免疫因子IFN-γ和IL-12表达量。结果:与模型组比较,金复康口服液中、高剂量组能够抑制肺癌移植瘤生长,抑瘤率分别是36.35%和28.59%; 金复康口服液中、高剂量组能明显降低肿瘤组织 PD-1、PD-L1 mRNA含量,抑制PD-1、PD-L1蛋白表达; HE染色显示中、高剂量组肺组织形态完整,未见明显癌巢; 中剂量组明显增加血清中IFN-γ和IL-12的含量。结论:金复康口服液对肺癌移植瘤的生长有一定抑制作用,机制可能与降低肿瘤微环境中PD-1、PD-L1水平并增加血清中免疫因子IFN-γ和IL-12的含量有关。
Abstract:
Objective:To observe the effects of Jinfukang oral liquid(JFK)on the expression of costimulatory molecule programmed receptor 1(PD-1),ligand(PD-L1)and related immune factors in tumor microenvironment of mice bearing Lewis lung carcinoma.Methods:The model of lung cancer subcutaneous allograft was established using Lewis lung cancer cells.After successful tumor implantation,the mice were randomly divided into four groups:A model group and low,medium,and high-dose groups of Chinese medicine,each group containing eight mice.On the first day of the experiment,the low-dose,the medium-dose,and the high-dose of Chinese medicine group were respectively given intragastric administration of 15,30,60 g/(kg·d),and the model group was administered with the same amount of normal saline once daily for 14 days.Tumors of each group were weighed and tumor inhibition rates were calculated.The expressions of PD-1,PD-L1 mRNA and protein in tumor tissues of mice were detected by real-time quantitative PCR and Western blotting,respectively.The lung tissue of mice were observed by HE staining.And IFN-γ and IL-12 expression in serum were detected by ELISA.Results:Compared with the model group,the medium and high dose group of JFK could inhibit tumor growth with tumor inhibition rate being 36.35%、28.59%,respectively.The medium and high doses of Jinfukang oral liquid could significantly decrease the expression of PD-1,PD-L1 mRNA and inhibited the expression of the PD-1/PD-L1 protein in tumor tissues; HE staining showed that the lung tissue morphology of the middle and high dose groups was complete,and no obvious cancer nest was observed.The middle dose group significantly increased the levels of IFN-γ and IL-12 in serum.Conclusion:Jinfukang oral liquid can inhibit the growth of the transplanted tumor by decreasing PD-1,PD-L1 level in tumor microenvironment and increasing IFN-γ and IL-12 levels in serum.

参考文献/References:

[1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] 蒋义鑫,徐 元,周之毅,等.金复康口服液诱导肺癌细胞A549凋亡的机制[J].中国实验方剂学杂志,2018,24(9):160-165.
[3] Freeman GJ,Long AJ,Iwai Y,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J].J Exp Med,2000,192(7):1027-1034.
[4] Latchman Y,Wood CR,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nat Immunol,2001,2(3):261-268.
[5] Lazar-molnar E,Scandiuzzi L,Basu I,et al.Structure-guided development of a high-affinity human programmed cell Death-1:implications for tumor immunotherapy[J].E Bio Medicine,2017(17):30-44.
[6] Yamazaki T,Akiba H,Iwai H,et al.Expression of programmed death 1 ligands by murine T cells and APC[J].J Immunol,2002,169(10):5538-5545.
[7] Ma W,Gilligan BM,Yuan J,et al.Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy[J].J Hematol Oncol,2016,9(1):47.
[8] Kim JM,Chen DS.Immune escape to PD-L1/PD-1 blockade:seven steps to success(or failure)[J].Ann Oncol,2016,27(8):1492-1504.
[9] Bersanelli M,Buti S.From targeting the tumor to targeting the immune system:transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis[J].World J Clin Oncol,2017,8(1):37-53.
[10] 闫风彩,金木兰,石 峰,等.PD-1/PD-L1在恶性肿瘤中的表达及研究进展[J].诊断病理学杂志,2019,26(1):61-65.
[11] 慕晓艳,白浩然,周晓辉,等.金复康口服液合软化汤联合化疗治疗气阴两虚型Ⅲb-Ⅳ期非小细胞肺癌[J].中国临床研究,2019,32(9):1271-1274.
[12] 王志超,曾进龙,张海良,等.金复康对晚期非小细胞肺癌患者肿瘤生长转移和血管内皮生成因子的影响[J].实用医院临床杂志,2011,8(4):148-149.
[13] 朱惠蓉,刘嘉湘.益肺抗瘤饮对Lewis肺癌荷瘤小鼠神经内分泌免疫的实验研究[J].上海中医药大学学报,2000,14(2):44-46.
[14] 阙祖俊,罗 斌,钱芳芳,等.金复康通过p16/RB信号通路诱导肺癌循环肿瘤细胞衰老[J].肿瘤,2018,38(3):215-221.
[15] 孙玺媛,孙建立,刘嘉湘.金复康口服液对Lewis肺腺癌荷瘤鼠脾细胞分泌Th1/Th2类细胞因子的影响[J].辽宁中医药大学学报,2008,10(9):160-162.

相似文献/References:

[1]刘春燕,罗小燕,刘慧玲.沙参麦冬汤加减辅助吉非替尼对老年晚期非小细胞肺癌患者免疫功能及不良反应的影响*[J].陕西中医,2020,(2):183.
　LIU Chunyan,LUO Xiaoyan,LIU Huiling..Effects of modified Shashen Maidong decoction combined with gefitinib on immune function and adverse reactions in elderly patients with advanced non-small cell lung cancer[J].,2020,(10):183.
[2]梁应凤,郭姗姗,张 丹,等.健脾益肾方对非小细胞肺癌细胞体外增殖凋亡作用的实验研究*[J].陕西中医,2020,(5):574.[doi:DOI:10.3969/j.issn.10007369.2020.05.006]
　LIANG Yingfeng,GUO Shanshan,ZHANG Dan,et al.Effect of Jianpi Yishen prescription on proliferation and apoptosis of non-small cell lung cancer cells in vitro[J].,2020,(10):574.[doi:DOI:10.3969/j.issn.10007369.2020.05.006]
[3]郑 阳,宿 濛,陈 涛,等.加味小陷胸汤基于核因子-κB信号通路对非小细胞肺癌荷瘤小鼠的影响实验研究[J].陕西中医,2021,(1):23.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.005]
　ZHENG Yang,SU Meng,CHEN Tao,et al.Effect of Jiawei Xiaoxianxiong decoction on non-small cell lung cancer mice based on NF-κB signaling pathway[J].,2021,(10):23.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.005]

备注/Memo

备注/Memo:
*国家十三五“重大新药创制”科技重大专项(2017ZX09304001)；上海中医药大学附属龙华医院科技创新项目(KY1938)
更新日期/Last Update: 2020-10-10